CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report)'s stock price dropped 0.5% during trading on Monday . The company traded as low as $43.25 and last traded at $43.70. Approximately 525,122 shares changed hands during mid-day trading, a decline of 77% from the average daily volume of 2,299,289 shares. The stock had previously closed at $43.92.
A number of brokerages have weighed in on CRSP. Cantor Fitzgerald reaffirmed a "neutral" rating on shares of CRISPR Therapeutics in a research note on Wednesday, February 19th. Chardan Capital cut their price objective on CRISPR Therapeutics from $94.00 to $84.00 and set a "buy" rating on the stock in a report on Thursday, February 13th. Evercore ISI raised CRISPR Therapeutics from an "in-line" rating to an "outperform" rating and lifted their price target for the company from $60.00 to $99.00 in a research note on Friday, February 14th. HC Wainwright restated a "buy" rating and set a $65.00 target price on shares of CRISPR Therapeutics in a report on Thursday, February 13th. Finally, Bank of America lowered their target price on shares of CRISPR Therapeutics from $98.00 to $85.00 and set a "buy" rating on the stock in a report on Tuesday, January 7th. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and twelve have assigned a buy rating to the stock. Based on data from MarketBeat.com, CRISPR Therapeutics has an average rating of "Hold" and a consensus target price of $74.40.
Check Out Our Latest Stock Report on CRSP
The stock has a market cap of $3.76 billion, a PE ratio of -10.03 and a beta of 1.67. The firm has a 50 day moving average price of $42.57 and a 200 day moving average price of $45.86.
CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last issued its quarterly earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. Equities analysts forecast that CRISPR Therapeutics AG will post -5.16 earnings per share for the current year.
In related news, CEO Samarth Kulkarni sold 18,360 shares of the business's stock in a transaction dated Wednesday, February 19th. The shares were sold at an average price of $55.20, for a total transaction of $1,013,472.00. Following the transaction, the chief executive officer now directly owns 171,613 shares in the company, valued at approximately $9,473,037.60. The trade was a 9.66 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director John Greene purchased 7,000 shares of the business's stock in a transaction dated Wednesday, February 26th. The shares were purchased at an average price of $44.85 per share, with a total value of $313,950.00. Following the acquisition, the director now directly owns 7,000 shares in the company, valued at approximately $313,950. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 4.10% of the company's stock.
Several hedge funds and other institutional investors have recently bought and sold shares of the business. Boston Family Office LLC increased its stake in shares of CRISPR Therapeutics by 2.2% during the third quarter. Boston Family Office LLC now owns 9,763 shares of the company's stock valued at $459,000 after acquiring an additional 213 shares during the period. Bedell Frazier Investment Counselling LLC lifted its position in shares of CRISPR Therapeutics by 0.8% in the 3rd quarter. Bedell Frazier Investment Counselling LLC now owns 26,357 shares of the company's stock valued at $1,238,000 after acquiring an additional 218 shares in the last quarter. The Manufacturers Life Insurance Company raised its position in CRISPR Therapeutics by 1.9% during the third quarter. The Manufacturers Life Insurance Company now owns 12,477 shares of the company's stock valued at $586,000 after buying an additional 231 shares during the period. Intellectus Partners LLC increased its stake in CRISPR Therapeutics by 3.6% in the 4th quarter. Intellectus Partners LLC now owns 7,131 shares of the company's stock valued at $281,000 after buying an additional 250 shares during the period. Finally, Farrow Financial Inc. grew its holdings in shares of CRISPR Therapeutics by 1.4% during the 4th quarter. Farrow Financial Inc. now owns 20,097 shares of the company's stock valued at $777,000 after acquiring an additional 270 shares in the last quarter. 69.20% of the stock is owned by hedge funds and other institutional investors.
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider CRISPR Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CRISPR Therapeutics wasn't on the list.
While CRISPR Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.